HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 07, July 2018 – Water management- Technologies for biotech and pharmaceutical industries       » Why sunshine improves mood and makes us smarter       » SGD110 million lab to create healthier foods and sustainable biochemicals       » Entries open for the USD170,000 Ryman Prize       » Could the eye be the window to brain degeneration?       » High vitamin D levels linked to lower cholesterol in children      
EYE ON CHINA
Shenzhen biotech companies building the world’s largest cell bank in Guizhou
Shenzhen biotech companies choose Guizhou Province in Southwest China for its policy support from the governments at all levels in Guizhou

Year 2017 is a year where the life sciences industry in the world opened new territories in different fields. Cellular immunotherapy has achieved a historic breakthrough and started clinical application. Gene editing has also moved from basic science research to technological applications. In China, clinical applications of CAR-T cell therapy have been submitted for regulatory approval, and the company that produced the first domestic PD-1 monoclonal antibody drug is also preparing for public listing. BGI Genomics (华大基因) was successfully listed on the Shenzhen Stock Exchange, 18 years since its founding; Beike Biotech (北科生物) announced that the Shenzhen Integrated Cell Bank was granted accreditation by the American Association of Blood Bank; Direct Genomics (瀚海基因) has released its GenoCare single-molecule sequencing platform, a third-generation gene sequencer.

Shenzhen is known as the "Silicon Valley" of China’s bio-industry. The city has witnessed an average annual growth rate of 20 per cent in the life science and healthcare sector in recent years. The output of the industry has exceeded 30 billion U.S. dollars. Currently Shenzhen's new generation of gene sequencing capabilities ranks the first in the world. The world’s largest gene bank, the China National Gene Bank, is located in Shenzhen. Tumor immunotherapy and other biotechnologies developed by Shenzhen companies are also industry leaders in mainland China.

To improve the competency of biotech companies, in 2016, over 70 companies in Shenzhen formed the first Life Science Industry Association in China. The plan is to integrate Shenzhen's high-quality life science resources and create an innovative industry model, to push the "full value chain of the life science industry".

To this end, Beike Biotech and Rong Hui Ren He (融汇仁和) have planned 12 large-scale industrial projects which are all located in the Guizhou province. The projects will combine medical and life science technologies as well as artificial intelligence to create an innovative industry model. Confirmed projects include the “Beike (Guiyang) Life Science Center”, “Beike Rong Hui (Dong Township) Life Science World: the World's Largest Cell Bank”, “Yi Long Innovative Hospital”, “Mei Tan Peach Blossom River Life Science Valley” and “Beike Life and Health Management College”. It was announced at the association’s meeting in January that the world's largest cell bank, with the capacity to store over 20 million cell samples, will be completed and put into use in June this year.

It is to be noted that these projects are not built by one enterprise alone, but the result of collaborative efforts involving a number of enterprises. Among the confirmed projects, the companies that are taking part include Beike Biotech, Rong Hui Ren He, BGI Genomics, Shenzhen Das Intellitech, Hui Kang Medical. For example, in the Beike (Guiyang) Life Science Center project, BGI will be in charge of setting up the genetic testing center, and Huikang Medical will use data analytics to mine the medical big data, helping doctors achieve precision diagnosis and treatment. “In the future, more members of the trade association will join in, to play their part in the national strategic direction of building the life-science industry, also to speed up the gaining of domestic market." Said Deputy Secretary Ding Leshi, Shenzhen Life Science Industry Association.

But why would Shenzhen biotech companies choose Guizhou Province in Southwest China as a base for such huge projects?

On the one hand, it is due to the policy support from the governments at all levels in Guizhou Province. Guizhou recognizes the health industry as one of the strategic emerging industries. There is unprecedented support in administrative examination and approval, land lease for projects, financial support, and preferential tax treatment.

Guizhou has lagged behind the national counterparts in terms of healthcare and medical services, and the government is determined to change this track record and treat the life sciences and healthcare industry as its core competencies. In February 2017, the capital city Guiyang signed a cooperation agreement with Beike Biotech to create a “City Life Valley” project. This is a project that integrates health management, healthy retirement, leisure and vacation, smart community services in one complex.

Guizhou also regards the development of big data industry as a strategic move and has taken the lead in medical data analytics. Coupled with Guizhou's ecological, landscape and climate resources, it has a major advantage.

In addition to driving the domestic market outside Shenzhen, the Life Sciences Industry Association is also planning to bring more projects to Shenzhen. “After all, Shenzhen has a better foundation for the development of the science and technology industry," said Ding. By working with counterparts in the bio-industry and pooling the resources together, it is possible for Shenzhen to accelerate the development of the life sciences industry and to compete in the global market.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management- Technologies for biotech and pharmaceutical industries
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy